Latest Promisia Healthcare (NZX:PHL) News

Speculative small caps drove the week, with Tasman Resources, Solis Minerals and Lithium Energy leading the board after funding, drilling and asset sale updates. At the other end, ASX Ltd and Arafura Rare Earths fell hard as investors reacted to higher costs and fresh equity issuance.

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.

Promisia Healthcare reported a robust 29% increase in operating revenue for FY26, alongside a new dividend policy tied to operating free cash flow, setting the stage for continued growth in FY27.

Big capital raisings, fresh trial data and a few boardroom shocks shaped healthcare trading this week. The biggest moves came from companies either fixing the balance sheet, explaining heavy selling, or pushing key drugs and devices closer to market.

Promisia Healthcare’s portfolio value jumps 17.1% to $107.2 million, driven by improved occupancy and operational efficiencies across all sites.

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.

Promisia Healthcare lifted its group-wide care occupancy to 94% in March 2026, driven by a strong turnaround at Nelson Street and steady performances at key sites. The company also nears completion of its Ranfurly Manor care suite sales program and greenlights solar panel installations to curb energy costs.